Breaking News

U.K. Economy Grew 0.8% in Second Quarter, Matching Forecast
Tweet TWEET

Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

 Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for
                          Canine Oncology Therapies

  PR Newswire

  UPPSALA, Sweden, January 9, 2013

UPPSALA, Sweden, January 9, 2013 /PRNewswire/ --

Oasmia and Abbott have entered into an exclusive global collaboration
agreement with respect to Oasmia's two leading animal health product
candidates, Paccal® Vet and Doxophos® Vet. The agreement significantly
expands the nature and scope of the initial collaboration that was initially
entered into in 2009 between Oasmia and Abbott regarding these products.

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/58670-Oasmia-Abbott-canine-oncology-agreement

Under the terms of the expanded agreement, Abbott Animal Health will obtain
exclusive license and distribution rights to the products for essentially the
entire world. In return, Oasmia will receive an upfront payment and is
eligible to receive additional milestone payments of up to $21.5M subject to
Oasmia meeting various product development and sales milestones. In addition,
in the event either or both of the products are commercialized, Oasmia shall
receive tiered royalties on net sales. Oasmia will continue to fund research,
development and manufacture of Paccal® Vet and Doxophos® Vet. 

- I am very pleased that we have reached this expanded agreement between our
companies. We will now have one world-class partner for essentially the entire
global canine oncology market. In addition to the well-established markets in
the industrialized countries, we believe that there is great future market
potential in developing countries as medical innovation allows dedicated
owners to treat emerging health issues in their beloved companion animals,
said Julian Aleksov, chief executive officer, Oasmia Pharmaceutical.

The agreement does not include the rights to Paccal® Vet in Russia, Japan and
the Commonwealth of Independent States (CIS), or the rights to Doxophos® Vet
in Russia and the CIS.

Cancer is the leading cause of canine disease-related deaths, with up to 3
million new cases diagnosed annually worldwide. Cancer accounts for nearly 50
percent of all deaths in dogs 10 years of age or older.

Video:
http://www.multivu.com/mnr/58670-Oasmia-Abbott-canine-oncology-agreement

Contact: For more information, please contact: Johan Edin, acting Head of
Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone:
+46 (0) 18 50 54 40. German contact: Dr. Sönke Knop, Peggy Kropmanns, edicto
GmbH, Frankfurt E-Mail: oasmia@edicto.de Phone: +49 (0) 69 90 55 05 52.
Information is also available at http://www.oasmia.com
http://www.nasdaqomxnordic.com http://www.boerse-frankfurt.de
twitter.com/oasmia